Patient Compliance to TKI Therapy
As TKIs are oral agents, nonadherence to the treatment schedule can be a concern, which can lead to poorer outcomes. Studies have been conducted on adherence rates of imatinib that distinctly demonstrate that higher doses of imatinib contribute to lower adherence, and lower adherence contributes to loss of durable responses (National Comprehensive Cancer Network, 2011).
Patient education and close follow-up to patient behaviors are key to proper adherence on any cancer therapy, including TKIs. Early and adequate responses to side effects can positively impact adherence rates. Consistent scheduling of follow-up appointments and demonstrating active awareness and encouragement of patient issues may also influence adherence.